Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10227238" target="_blank" >RIV/00179906:_____/14:10227238 - isvavai.cz</a>
Alternative codes found
RIV/60162694:G44__/14:43875252
Result on the web
<a href="http://dx.doi.org/10.2174/9781608058228114060003" target="_blank" >http://dx.doi.org/10.2174/9781608058228114060003</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/9781608058228114060003" target="_blank" >10.2174/9781608058228114060003</a>

Result language
angličtina
Original language name
Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives
Original language description
Alzheimer's disease (AD) is a multifactorial disorder and apparently involves several different etiopathogenetic mechanisms. Up-to-date, there are no curative treatments or effective disease modifying therapies for AD. A strategy to enhance the cholinergic transmission by using acetylcholinesterase inhibitors (AChEIs) has been proposed more than two decades ago. Food and Drug Administration (FDA) gradually marketed these AChEIs: tacrine (1993), donepezil (1997), rivastigmine (2000) and galantamine (2001); tacrine is no longer used because of its high prevalence of hepatotoxicity. In addition to the AD cholinergic hypothesis , there is great evidence that voltage-gated, uncompetitive, N-methyl-D-aspartate (NMDA) antagonist memantine with moderate affinity can protect neurons from excitotoxicity. It was approved by FDA for treatment of moderate to severe stages of AD in 2003. Beyond symptomatic approaches there are anti-amyloid, neuroprotective and neuron-restorative strategies that hold
Czech name
—
Czech description
—

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)